Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;18 Suppl 2(Suppl 2):S5-S10.
doi: 10.3747/co.v18is2.941.

Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer

S Gill  1 , S Berry, J Biagi, C Butts, M Buyse, E Chen, D Jonker, C Mărginean, B Samson, J Stewart, M Thirlwell, R Wong, J A Maroun
Affiliations

Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer

S Gill et al. Curr Oncol. 2011 Oct.

Abstract

In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement in overall survival has been considered the "gold standard"-the most convincing measure of efficacy. However, overall survival requires larger patient numbers and longer follow-up and may often be confounded by other factors, including subsequent therapies and crossover. Given the number of active therapies for potential investigation, demand for rapid evaluation and early availability of new therapies is growing. Progression-free survival is regarded as an important measure of treatment benefit and, compared with overall survival, can be evaluated earlier, with fewer patients and no confounding by subsequent lines of therapy. The present paper reviews the advantages, limitations, and relevance of progression-free survival as a primary endpoint in randomized trials of metastatic colorectal cancer.

Keywords: Progression-free survival; metastatic colorectal cancer; randomized clinical trials; surrogate endpoints; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

9. CONFLICT OF INTEREST DISCLOSURES

MB holds stock in iddi. JAM has received research funding from Roche and Sanofi–Aventis, and has received honoraria for participation on boards and as a speaker for Roche, Novartis, Amgen, and Sanofi–Aventis. The remaining authors have no conflicts of interest pertinent to the topic of this manuscript to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005.
    1. Rothbarth J, van de Velde CJ. Treatment of liver metastases of colorectal cancer. Ann Oncol. 2005;16(suppl 2):ii144–9. doi: 10.1093/annonc/mdi702. - DOI - PubMed
    1. Paschos KA, Bird N. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. Hippokratia. 2008;12:132–8. - PMC - PubMed
    1. McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol. 2007;16:3–5. doi: 10.1016/j.suronc.2007.04.008. - DOI - PubMed
    1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47. - PubMed

LinkOut - more resources